The gene therapy landscape is expanding rapidly, but manufacturing costs remain the primary barrier to commercial and clinical accessibility. Therapy developers must rethink upstream strategy to reduce cost per dose without compromising quality. Early‑stage companies and emerging developers often struggle to scale beyond research formats, while CDMOs face pressure to expand capacity, increase flexibility, and accelerate tech transfer.
This webinar explores data‑driven, scalable, upstream solutions for transient AAV production, integrating insights from the iCELLis™ fixed‑bed platform, scalable Xcellerex™ X‑platform stirred‑tank bioreactors, and enhanced transient transfection workflows.
Register for free to get video access
Pankaj Salvi
Pankaj Salvi holds a Master’s degree in Microbiology from the University of Pune and has over 17 years of experience in the biotechnology industry. He is currently a Workflow Development Specialist for the Asia-Pacific region at Cytiva, supporting customers in optimizing genomic medicine workflows and adopting innovative technologies across the region.
During his tenure at Cytiva, Pankaj has held several technical roles, including Biotech Specialist, Senior Bioreactor Application Scientist, and Genomic Medicine Field Application Scientist, contributing to application support, customer success, and technology adoption in bioprocessing and genomic medicine.
Previously, he worked as a Process Development Researcher at Lupin Ltd., building strong upstream and downstream process development expertise. His technical background spans recombinant proteins, monoclonal antibodies, vaccines, viral vectors, and cell therapy, complemented by a strong techno commercial perspective. Outside work, he enjoys family time, travel, swimming, and terrace gardening.
Kelly Cybulski
Kelly.Cybulski@Cytiva.com
Senior Scientist, R&D, Cytiva
Kelly Cybulski is a Senior Scientist in R&D at Cytiva. She holds a Master of Science degree in Cell and Molecular Biology from the University of Rhode Island and brings 19 years of experience spanning GMP manufacturing, process development, and research and development. Over the past six years at Cytiva, Kelly has specialized in viral vector process and product development, contributing deep technical expertise to advancing scalable and robust solutions.
Emmanuelle Cameau
emmanuelle.cameau@cytiva.com
Scientific Director – Viral Vectors, Cytiva
Emmanuelle is driven to solve customer challenges such as how to reduce manufacturing burdens through process improvement and innovative solutions. She has a proven track record and 19+ years of experience in process development and the manufacturing of biologics and advanced therapies, especially viral vectors and stem cells, and currently works for Cytiva as Scientific Director, Viral Vectors.